Show simple item record

dc.contributor.authorMirzababaee, M
dc.contributor.authorShafiei, B
dc.contributor.authorSeifollahi, S
dc.contributor.authorMotazdian, M
dc.contributor.authorFatholahi, L
dc.contributor.authorDelavari, S
dc.contributor.authorNaghshine, R
dc.contributor.authorBaharfar, N
dc.contributor.authorTabeie, F
dc.contributor.authorJavadi, H
dc.contributor.authorAssadi, M
dc.contributor.authorAsli, IN
dc.date.accessioned2018-08-26T09:00:32Z
dc.date.available2018-08-26T09:00:32Z
dc.date.issued2014
dc.identifier.urihttp://dspace.tbzmed.ac.ir:8080/xmlui/handle/123456789/54920
dc.description.abstractObjective: To compare safety and efficacy of pantoprazol, metoclopramide, ondansetron, as compared to placebo, in controlling gastrointestinal (GI) complaints of thyroid cancer patients treated with I-131these patients. Design: Four-armed, parallel group, single blind, randomized controlled clinical trial, setting: A university hospital, registration: database for clinical trials IRCT2013061713705N1. Patients: 85 patients with differentiated thyroid cancer who received131I. Main outcome measures: Post-radioiodine nausea and vomiting within three days of therapy (primary endpoint); occurrence of adverse reaction. Results: The patients’ characteristics were similar within the study groups. Among the study variables, age, sex, administered dosage, history of previous GI complaints, and history of hyper -emesis gravidarum in female patients were not statistically different among the groups (p > 0.05). The results revealed that only ond-ansetron shows a therapeutic benefit over the placebo in controlling nausea (p < 0.05); however, it does not prevent vomiting (p > 0.05). The other two drugs, pantoprazole and meto-clopramide, did not control nausea (p > 0.05) or vomiting (p > 0.05). Conclusions: This study may demonstrate that the therapeutic dose of ondansetron could be an effective prophylactic agent in controlling GI complaints in differential thyroid carcinoma (DTC) patients following RAI therapy; however, these pre -liminary findings should be validated in larger studies. © Schattauer 2014.
dc.language.isoEnglish
dc.relation.ispartofNuklearMedizin
dc.subjectiodine 131
dc.subjectmetoclopramide
dc.subjectondansetron
dc.subjectpantoprazole
dc.subjectplacebo
dc.subject2 [[(2 pyridyl)methyl]sulfinyl]benzimidazole derivative
dc.subjectantiemetic agent
dc.subjectmetoclopramide
dc.subjectondansetron
dc.subjectpantoprazole
dc.subjectproton pump inhibitor
dc.subjectradioactive iodine
dc.subjectradiopharmaceutical agent
dc.subjectadult
dc.subjectArticle
dc.subjectchemotherapy induced nausea and vomiting
dc.subjectcomparative study
dc.subjectdifferentiated thyroid cancer
dc.subjectdrug efficacy
dc.subjectdrug safety
dc.subjectfemale
dc.subjectfollicular carcinoma
dc.subjectgastrointestinal symptom
dc.subjecthuman
dc.subjecthurthle cell thyroid cancer
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectmiddle aged
dc.subjectnausea
dc.subjectnausea and vomiting
dc.subjectrandomized controlled trial
dc.subjectsingle blind procedure
dc.subjectthyroid follicular carcinoma
dc.subjectthyroid papillary carcinoma
dc.subjectcomplication
dc.subjectcontrolled study
dc.subjectGastrointestinal Diseases
dc.subjectRadiation Injuries
dc.subjectThyroid Neoplasms
dc.subjecttreatment outcome
dc.subject2-Pyridinylmethylsulfinylbenzimidazoles
dc.subjectAntiemetics
dc.subjectFemale
dc.subjectGastrointestinal Diseases
dc.subjectHumans
dc.subjectIodine Radioisotopes
dc.subjectMale
dc.subjectMetoclopramide
dc.subjectMiddle Aged
dc.subjectOndansetron
dc.subjectProton Pump Inhibitors
dc.subjectRadiation Injuries
dc.subjectRadiopharmaceuticals
dc.subjectThyroid Neoplasms
dc.subjectTreatment Outcome
dc.titleManagement of gastrointestinal complaints in differentiated thyroid cancer patients treated with 131I: Comparison of the efficacy of pantoprazole, metoclopra-mide, and ondansetron – a randomized clinical trial [Behandlung gastrointestinaler beschwerden unter 131I-therapie bei patienten mit differenzier-tem schilddrüsenkarzinom: Vergleich der wirksamkeit von pantoprazol, meto-clopramid und ondansetron – eine randomisierte klinische prüfung]
dc.typeArticle
dc.citation.volume53
dc.citation.issue5
dc.citation.spage186
dc.citation.epage189
dc.citation.indexScopus
dc.identifier.DOIhttps://doi.org/10.3413/Nukmed-0654-14-03


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record